Nancy Lynn Snyderman MD - 31 May 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Reporting relationship: Director
Issuer ticker: ALKS
Reported as of: 31 May 2024
Net transaction value: +$114,611
SEC form: 4
Accepted by SEC: 04 Jun 2024, 17:01:28 UTC
Prior SEC filing: 10 Jul 2023
Next SEC filing: 14 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Shantale Greenson, attorney-in-fact for Nancy Snyderman

Key filing fact

Nancy Lynn Snyderman MD filed Form 4 for Alkermes plc. (ALKS) on 04 Jun 2024.

Key facts

This page summarizes Nancy Lynn Snyderman MD's Form 4 filing for Alkermes plc. (ALKS).
13 reported transactions and 13 derivative rows are listed below.
Accepted by SEC: 04 Jun 2024, 17:01.

Change

Previous filing in this sequence was filed on 10 Jul 2023.
Current net transaction value: +$114,611.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $25,603
Shares: +548
Change %: +2%
Price: $46.72
Shares after: 27,948
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 548
Exercise price: $46.72
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $15,137
Shares: +324
Change %: +2%
Price: $46.72
Shares after: 16,524
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 324
Exercise price: $46.72
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $16,219
Shares: +284
Change %: +2%
Price: $57.11
Shares after: 14,484
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 284
Exercise price: $57.11
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $15,662
Shares: +350
Change %: +2%
Price: $44.75
Shares after: 17,850
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 350
Exercise price: $44.75
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $10,998
Shares: +448
Change %: +2%
Price: $24.55
Shares after: 22,848
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 448
Exercise price: $24.55
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $4,229
Shares: +256
Change %: +2%
Price: $16.52
Shares after: 13,079
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 256
Exercise price: $16.52
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $4,244
Shares: +230
Change %: +2%
Price: $18.45
Shares after: 11,739
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 230
Exercise price: $18.45
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $7,587
Shares: +313
Change %: +2%
Price: $24.24
Shares after: 15,990
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 313
Exercise price: $24.24
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $7,129
Shares: +231
Change %: +2%
Price: $30.86
Shares after: 11,785
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 231
Exercise price: $30.86
Footnotes: F1, F2

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Other

Transaction value: $7,803
Shares: +254
Change %: +2%
Price: $30.72
Shares after: 12,986
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 254
Exercise price: $30.72
Footnotes: F1, F3

ALKS transaction Derivative

Restricted Stock Unit Award

Other

Transaction value
Shares: +119
Change %: +2%
Price
Shares after: 6,104
Date: 17 Nov 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 119
Exercise price
Footnotes: F1, F4, F5

ALKS transaction Derivative

Restricted Stock Unit Award

Award

Transaction value: $0
Shares: +8,013
Change %
Price: $0.000000
Shares after: 8,013
Date: 31 May 2024
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 8,013
Exercise price
Footnotes: F4, F6

ALKS transaction Derivative

Non Qualified Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,492
Change %
Price: $0.000000
Shares after: 17,492
Date: 31 May 2024
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 17,492
Exercise price: $23.40
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

Footnote F2

These options are fully vested in accordance with their terms.

Footnote F3

Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

Footnote F4

Each restricted stock unit represents a contingent right to receive one ordinary share.

Footnote F5

Shares subject to the restricted stock unit award vest in full on 6/29/2024.

Footnote F6

Shares subject to the restricted stock unit award vest in full on 5/31/2025.

Footnote F7

Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.

SEC remarks

EXHIBIT LIST: Exhibit 24.1 - Power of Attorney